nodes	percent_of_prediction	percent_of_DWPC	metapath
Valganciclovir—SLC6A14—Amino acid transport across the plasma membrane—SLC7A1—prostate cancer	0.0145	0.0808	CbGpPWpGaD
Valganciclovir—SLC6A14—Amino acid and oligopeptide SLC transporters—SLC7A1—prostate cancer	0.01	0.056	CbGpPWpGaD
Valganciclovir—SLC6A14—Na+/Cl- dependent neurotransmitter transporters—SLC22A1—prostate cancer	0.00888	0.0496	CbGpPWpGaD
Valganciclovir—SLC6A14—Amine compound SLC transporters—SLC22A1—prostate cancer	0.00616	0.0344	CbGpPWpGaD
Valganciclovir—SLC6A14—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC7A1—prostate cancer	0.0059	0.033	CbGpPWpGaD
Valganciclovir—Ganciclovir—SLC22A1—prostate cancer	0.00495	0.562	CrCbGaD
Valganciclovir—SLC15A2—Amino acid and oligopeptide SLC transporters—SLC7A1—prostate cancer	0.00474	0.0265	CbGpPWpGaD
Valganciclovir—SLC6A14—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC39A1—prostate cancer	0.00459	0.0256	CbGpPWpGaD
Valganciclovir—SLC15A1—Amino acid and oligopeptide SLC transporters—SLC7A1—prostate cancer	0.0044	0.0246	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—CBR1—prostate cancer	0.00418	0.0234	CbGpPWpGaD
Valganciclovir—Aciclovir—SLC22A1—prostate cancer	0.00385	0.437	CrCbGaD
Valganciclovir—SLC6A14—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC26A4—prostate cancer	0.00371	0.0207	CbGpPWpGaD
Valganciclovir—SLC6A14—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC12A2—prostate cancer	0.00371	0.0207	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—GSTM3—prostate cancer	0.00366	0.0204	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—SLC39A1—prostate cancer	0.00331	0.0185	CbGpPWpGaD
Valganciclovir—SLC6A14—Imatinib Resistance in Chronic Myeloid Leukemia—GADD45A—prostate cancer	0.00309	0.0172	CbGpPWpGaD
Valganciclovir—SLC6A14—Amino acid and oligopeptide SLC transporters—SLC5A5—prostate cancer	0.00304	0.017	CbGpPWpGaD
Valganciclovir—SLC6A14—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A3—prostate cancer	0.00296	0.0165	CbGpPWpGaD
Valganciclovir—SLC15A2—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC7A1—prostate cancer	0.00279	0.0156	CbGpPWpGaD
Valganciclovir—SLC6A14—SLC-mediated transmembrane transport—SLC7A1—prostate cancer	0.00264	0.0147	CbGpPWpGaD
Valganciclovir—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC7A1—prostate cancer	0.00259	0.0145	CbGpPWpGaD
Valganciclovir—SLC6A14—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A1—prostate cancer	0.00241	0.0135	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—GSTA3—prostate cancer	0.00223	0.0125	CbGpPWpGaD
Valganciclovir—SLC6A14—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRB—prostate cancer	0.00219	0.0122	CbGpPWpGaD
Valganciclovir—SLC6A14—SLC-mediated transmembrane transport—SLC39A1—prostate cancer	0.00208	0.0117	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—GSTA4—prostate cancer	0.00204	0.0114	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—GSTA2—prostate cancer	0.00199	0.0111	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—GSTA1—prostate cancer	0.00192	0.0107	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—HSP90AB1—prostate cancer	0.00186	0.0104	CbGpPWpGaD
Valganciclovir—SLC6A14—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC5A5—prostate cancer	0.00179	0.00999	CbGpPWpGaD
Valganciclovir—SLC15A2—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC12A2—prostate cancer	0.00175	0.0098	CbGpPWpGaD
Valganciclovir—SLC15A2—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC26A4—prostate cancer	0.00175	0.0098	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—NFE2L2—prostate cancer	0.00169	0.00946	CbGpPWpGaD
Valganciclovir—SLC6A14—SLC-mediated transmembrane transport—SLC26A4—prostate cancer	0.00166	0.00926	CbGpPWpGaD
Valganciclovir—SLC6A14—SLC-mediated transmembrane transport—SLC12A2—prostate cancer	0.00166	0.00926	CbGpPWpGaD
Valganciclovir—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC12A2—prostate cancer	0.00163	0.00909	CbGpPWpGaD
Valganciclovir—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC26A4—prostate cancer	0.00163	0.00909	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—TGFA—prostate cancer	0.00162	0.00903	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—GPX3—prostate cancer	0.00162	0.00903	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—CYP2A6—prostate cancer	0.00146	0.00814	CbGpPWpGaD
Valganciclovir—SLC15A2—Amino acid and oligopeptide SLC transporters—SLC5A5—prostate cancer	0.00144	0.00802	CbGpPWpGaD
Valganciclovir—SLC6A14—SLC-mediated transmembrane transport—SLC22A3—prostate cancer	0.00134	0.00751	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—SLC7A1—prostate cancer	0.00134	0.00749	CbGpPWpGaD
Valganciclovir—SLC15A1—Amino acid and oligopeptide SLC transporters—SLC5A5—prostate cancer	0.00133	0.00745	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—SLC5A5—prostate cancer	0.00127	0.00708	CbGpPWpGaD
Valganciclovir—SLC15A2—SLC-mediated transmembrane transport—SLC7A1—prostate cancer	0.00125	0.00697	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—NQO1—prostate cancer	0.00122	0.00684	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—HSPA1A—prostate cancer	0.00122	0.00679	CbGpPWpGaD
Valganciclovir—SLC6A14—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—prostate cancer	0.0012	0.00671	CbGpPWpGaD
Valganciclovir—SLC15A1—SLC-mediated transmembrane transport—SLC7A1—prostate cancer	0.00116	0.00647	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—EGR1—prostate cancer	0.00114	0.00635	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—GGT1—prostate cancer	0.00114	0.00635	CbGpPWpGaD
Valganciclovir—SLC6A14—SLC-mediated transmembrane transport—SLC22A1—prostate cancer	0.00109	0.00612	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—RXRA—prostate cancer	0.00106	0.00595	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—SLC39A1—prostate cancer	0.00106	0.00592	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—TGFBR2—prostate cancer	0.00102	0.00571	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—GSTP1—prostate cancer	0.00102	0.00571	CbGpPWpGaD
Valganciclovir—SLC15A2—SLC-mediated transmembrane transport—SLC39A1—prostate cancer	0.000986	0.00551	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—GSTM1—prostate cancer	0.000938	0.00524	CbGpPWpGaD
Valganciclovir—SLC6A14—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—prostate cancer	0.000918	0.00513	CbGpPWpGaD
Valganciclovir—SLC15A1—SLC-mediated transmembrane transport—SLC39A1—prostate cancer	0.000915	0.00511	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—CYP7B1—prostate cancer	0.000863	0.00483	CbGpPWpGaD
Valganciclovir—SLC15A2—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC5A5—prostate cancer	0.000845	0.00473	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—SLC26A4—prostate cancer	0.000841	0.0047	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—SLC12A2—prostate cancer	0.000841	0.0047	CbGpPWpGaD
Valganciclovir—SLC6A14—SLC-mediated transmembrane transport—SLC5A5—prostate cancer	0.000799	0.00446	CbGpPWpGaD
Valganciclovir—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC5A5—prostate cancer	0.000785	0.00439	CbGpPWpGaD
Valganciclovir—SLC15A2—SLC-mediated transmembrane transport—SLC26A4—prostate cancer	0.000783	0.00438	CbGpPWpGaD
Valganciclovir—SLC15A2—SLC-mediated transmembrane transport—SLC12A2—prostate cancer	0.000783	0.00438	CbGpPWpGaD
Valganciclovir—SLC15A1—SLC-mediated transmembrane transport—SLC12A2—prostate cancer	0.000727	0.00406	CbGpPWpGaD
Valganciclovir—SLC15A1—SLC-mediated transmembrane transport—SLC26A4—prostate cancer	0.000727	0.00406	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—SLC22A3—prostate cancer	0.000683	0.00381	CbGpPWpGaD
Valganciclovir—SLC15A2—SLC-mediated transmembrane transport—SLC22A3—prostate cancer	0.000635	0.00355	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—SLC7A1—prostate cancer	0.000634	0.00354	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—ABCG5—prostate cancer	0.00063	0.00352	CbGpPWpGaD
Valganciclovir—SLC15A1—SLC-mediated transmembrane transport—SLC22A3—prostate cancer	0.00059	0.0033	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—SLC7A1—prostate cancer	0.000588	0.00329	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—SLC22A1—prostate cancer	0.000556	0.00311	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—GNG5—prostate cancer	0.000529	0.00296	CbGpPWpGaD
Valganciclovir—SLC15A2—SLC-mediated transmembrane transport—SLC22A1—prostate cancer	0.000518	0.00289	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—SLC39A1—prostate cancer	0.000501	0.0028	CbGpPWpGaD
Valganciclovir—SLC15A1—SLC-mediated transmembrane transport—SLC22A1—prostate cancer	0.000481	0.00269	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—SLC39A1—prostate cancer	0.000465	0.0026	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—PRKACB—prostate cancer	0.000451	0.00252	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—NCOA2—prostate cancer	0.000425	0.00238	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—CYP7B1—prostate cancer	0.000408	0.00228	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—SLC5A5—prostate cancer	0.000406	0.00227	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—SLC12A2—prostate cancer	0.000398	0.00222	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—SLC26A4—prostate cancer	0.000398	0.00222	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—TGFB1—prostate cancer	0.000382	0.00214	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—CYP7B1—prostate cancer	0.000379	0.00212	CbGpPWpGaD
Valganciclovir—SLC15A2—SLC-mediated transmembrane transport—SLC5A5—prostate cancer	0.000378	0.00211	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—SLC12A2—prostate cancer	0.000369	0.00206	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—SLC26A4—prostate cancer	0.000369	0.00206	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—NCOA1—prostate cancer	0.000359	0.002	CbGpPWpGaD
Valganciclovir—SLC15A1—SLC-mediated transmembrane transport—SLC5A5—prostate cancer	0.000351	0.00196	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—RXRA—prostate cancer	0.000341	0.00191	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—SLC22A3—prostate cancer	0.000323	0.0018	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—SLC22A3—prostate cancer	0.0003	0.00167	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—ABCG5—prostate cancer	0.000298	0.00167	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—ABCG5—prostate cancer	0.000277	0.00155	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—SLC22A1—prostate cancer	0.000263	0.00147	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—PPARA—prostate cancer	0.000261	0.00146	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—GNG5—prostate cancer	0.00025	0.0014	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—SLC22A1—prostate cancer	0.000244	0.00137	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—GNG5—prostate cancer	0.000232	0.0013	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—PRKACB—prostate cancer	0.000213	0.00119	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—CREBBP—prostate cancer	0.000207	0.00116	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—NCOA2—prostate cancer	0.000201	0.00112	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—PRKACB—prostate cancer	0.000198	0.00111	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—SLC5A5—prostate cancer	0.000192	0.00107	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—NCOA2—prostate cancer	0.000187	0.00104	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—SLC5A5—prostate cancer	0.000178	0.000996	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—NCOA1—prostate cancer	0.00017	0.000948	CbGpPWpGaD
Valganciclovir—Haematuria—Doxorubicin—prostate cancer	0.000167	0.000205	CcSEcCtD
Valganciclovir—Connective tissue disorder—Epirubicin—prostate cancer	0.000167	0.000205	CcSEcCtD
Valganciclovir—Urethral disorder—Epirubicin—prostate cancer	0.000166	0.000205	CcSEcCtD
Valganciclovir—Hepatobiliary disease—Doxorubicin—prostate cancer	0.000165	0.000203	CcSEcCtD
Valganciclovir—Anorexia—Capecitabine—prostate cancer	0.000165	0.000203	CcSEcCtD
Valganciclovir—Nausea—Estradiol—prostate cancer	0.000165	0.000203	CcSEcCtD
Valganciclovir—Vomiting—Mitoxantrone—prostate cancer	0.000164	0.000202	CcSEcCtD
Valganciclovir—Sinusitis—Doxorubicin—prostate cancer	0.000164	0.000202	CcSEcCtD
Valganciclovir—Convulsion—Prednisone—prostate cancer	0.000163	0.000201	CcSEcCtD
Valganciclovir—Visual impairment—Epirubicin—prostate cancer	0.000163	0.000201	CcSEcCtD
Valganciclovir—Hypertension—Prednisone—prostate cancer	0.000163	0.0002	CcSEcCtD
Valganciclovir—Dermatitis—Mitoxantrone—prostate cancer	0.000163	0.0002	CcSEcCtD
Valganciclovir—Musculoskeletal discomfort—Docetaxel—prostate cancer	0.000163	0.0002	CcSEcCtD
Valganciclovir—Headache—Mitoxantrone—prostate cancer	0.000162	0.000199	CcSEcCtD
Valganciclovir—Hypotension—Capecitabine—prostate cancer	0.000161	0.000199	CcSEcCtD
Valganciclovir—Insomnia—Docetaxel—prostate cancer	0.000161	0.000199	CcSEcCtD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—RXRA—prostate cancer	0.000161	0.000902	CbGpPWpGaD
Valganciclovir—Arthralgia—Prednisone—prostate cancer	0.000161	0.000198	CcSEcCtD
Valganciclovir—Paraesthesia—Docetaxel—prostate cancer	0.00016	0.000197	CcSEcCtD
Valganciclovir—Anxiety—Prednisone—prostate cancer	0.00016	0.000197	CcSEcCtD
Valganciclovir—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	0.000159	0.000196	CcSEcCtD
Valganciclovir—Dyspnoea—Docetaxel—prostate cancer	0.000159	0.000196	CcSEcCtD
Valganciclovir—Somnolence—Docetaxel—prostate cancer	0.000159	0.000195	CcSEcCtD
Valganciclovir—Discomfort—Prednisone—prostate cancer	0.000159	0.000195	CcSEcCtD
Valganciclovir—Eye disorder—Epirubicin—prostate cancer	0.000158	0.000195	CcSEcCtD
Valganciclovir—Hypersensitivity—Etoposide—prostate cancer	0.000158	0.000195	CcSEcCtD
Valganciclovir—Tinnitus—Epirubicin—prostate cancer	0.000158	0.000195	CcSEcCtD
Valganciclovir—Haemoglobin—Doxorubicin—prostate cancer	0.000158	0.000194	CcSEcCtD
Valganciclovir—Musculoskeletal discomfort—Capecitabine—prostate cancer	0.000157	0.000194	CcSEcCtD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—NCOA1—prostate cancer	0.000157	0.00088	CbGpPWpGaD
Valganciclovir—Cardiac disorder—Epirubicin—prostate cancer	0.000157	0.000194	CcSEcCtD
Valganciclovir—Dyspepsia—Docetaxel—prostate cancer	0.000157	0.000193	CcSEcCtD
Valganciclovir—Haemorrhage—Doxorubicin—prostate cancer	0.000157	0.000193	CcSEcCtD
Valganciclovir—Hepatitis—Doxorubicin—prostate cancer	0.000157	0.000193	CcSEcCtD
Valganciclovir—Insomnia—Capecitabine—prostate cancer	0.000156	0.000192	CcSEcCtD
Valganciclovir—Pharyngitis—Doxorubicin—prostate cancer	0.000156	0.000192	CcSEcCtD
Valganciclovir—Paraesthesia—Capecitabine—prostate cancer	0.000155	0.000191	CcSEcCtD
Valganciclovir—Decreased appetite—Docetaxel—prostate cancer	0.000155	0.000191	CcSEcCtD
Valganciclovir—Urinary tract disorder—Doxorubicin—prostate cancer	0.000155	0.000191	CcSEcCtD
Valganciclovir—Oedema peripheral—Doxorubicin—prostate cancer	0.000154	0.00019	CcSEcCtD
Valganciclovir—Gastrointestinal disorder—Docetaxel—prostate cancer	0.000154	0.00019	CcSEcCtD
Valganciclovir—Asthenia—Etoposide—prostate cancer	0.000154	0.00019	CcSEcCtD
Valganciclovir—Connective tissue disorder—Doxorubicin—prostate cancer	0.000154	0.00019	CcSEcCtD
Valganciclovir—Dyspnoea—Capecitabine—prostate cancer	0.000154	0.00019	CcSEcCtD
Valganciclovir—Anaphylactic shock—Prednisone—prostate cancer	0.000154	0.00019	CcSEcCtD
Valganciclovir—Oedema—Prednisone—prostate cancer	0.000154	0.00019	CcSEcCtD
Valganciclovir—Fatigue—Docetaxel—prostate cancer	0.000154	0.000189	CcSEcCtD
Valganciclovir—Angiopathy—Epirubicin—prostate cancer	0.000154	0.000189	CcSEcCtD
Valganciclovir—Urethral disorder—Doxorubicin—prostate cancer	0.000154	0.000189	CcSEcCtD
Valganciclovir—Nausea—Mitoxantrone—prostate cancer	0.000153	0.000189	CcSEcCtD
Valganciclovir—Immune system disorder—Epirubicin—prostate cancer	0.000153	0.000188	CcSEcCtD
Valganciclovir—Infection—Prednisone—prostate cancer	0.000153	0.000188	CcSEcCtD
Valganciclovir—Mediastinal disorder—Epirubicin—prostate cancer	0.000153	0.000188	CcSEcCtD
Valganciclovir—Constipation—Docetaxel—prostate cancer	0.000153	0.000188	CcSEcCtD
Valganciclovir—Pain—Docetaxel—prostate cancer	0.000153	0.000188	CcSEcCtD
Valganciclovir—Dyspepsia—Capecitabine—prostate cancer	0.000152	0.000187	CcSEcCtD
Valganciclovir—Chills—Epirubicin—prostate cancer	0.000152	0.000187	CcSEcCtD
Valganciclovir—Pruritus—Etoposide—prostate cancer	0.000152	0.000187	CcSEcCtD
Valganciclovir—Arrhythmia—Epirubicin—prostate cancer	0.000151	0.000186	CcSEcCtD
Valganciclovir—Visual impairment—Doxorubicin—prostate cancer	0.000151	0.000186	CcSEcCtD
Valganciclovir—Nervous system disorder—Prednisone—prostate cancer	0.000151	0.000186	CcSEcCtD
Valganciclovir—Tachycardia—Prednisone—prostate cancer	0.00015	0.000185	CcSEcCtD
Valganciclovir—Decreased appetite—Capecitabine—prostate cancer	0.00015	0.000185	CcSEcCtD
Valganciclovir—Alopecia—Epirubicin—prostate cancer	0.00015	0.000184	CcSEcCtD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—RXRA—prostate cancer	0.00015	0.000837	CbGpPWpGaD
Valganciclovir—Skin disorder—Prednisone—prostate cancer	0.00015	0.000184	CcSEcCtD
Valganciclovir—Gastrointestinal disorder—Capecitabine—prostate cancer	0.000149	0.000184	CcSEcCtD
Valganciclovir—Fatigue—Capecitabine—prostate cancer	0.000149	0.000183	CcSEcCtD
Valganciclovir—Hyperhidrosis—Prednisone—prostate cancer	0.000149	0.000183	CcSEcCtD
Valganciclovir—Mental disorder—Epirubicin—prostate cancer	0.000148	0.000183	CcSEcCtD
Valganciclovir—Pain—Capecitabine—prostate cancer	0.000148	0.000182	CcSEcCtD
Valganciclovir—Constipation—Capecitabine—prostate cancer	0.000148	0.000182	CcSEcCtD
Valganciclovir—Malnutrition—Epirubicin—prostate cancer	0.000148	0.000182	CcSEcCtD
Valganciclovir—Feeling abnormal—Docetaxel—prostate cancer	0.000147	0.000181	CcSEcCtD
Valganciclovir—Diarrhoea—Etoposide—prostate cancer	0.000147	0.000181	CcSEcCtD
Valganciclovir—Anorexia—Prednisone—prostate cancer	0.000147	0.000181	CcSEcCtD
Valganciclovir—Eye disorder—Doxorubicin—prostate cancer	0.000147	0.00018	CcSEcCtD
Valganciclovir—Tinnitus—Doxorubicin—prostate cancer	0.000146	0.00018	CcSEcCtD
Valganciclovir—Gastrointestinal pain—Docetaxel—prostate cancer	0.000146	0.00018	CcSEcCtD
Valganciclovir—Cardiac disorder—Doxorubicin—prostate cancer	0.000146	0.000179	CcSEcCtD
Valganciclovir—Flatulence—Epirubicin—prostate cancer	0.000145	0.000179	CcSEcCtD
Valganciclovir—Tension—Epirubicin—prostate cancer	0.000145	0.000178	CcSEcCtD
Valganciclovir—Dysgeusia—Epirubicin—prostate cancer	0.000144	0.000178	CcSEcCtD
Valganciclovir—Nervousness—Epirubicin—prostate cancer	0.000143	0.000176	CcSEcCtD
Valganciclovir—Back pain—Epirubicin—prostate cancer	0.000143	0.000176	CcSEcCtD
Valganciclovir—Feeling abnormal—Capecitabine—prostate cancer	0.000142	0.000175	CcSEcCtD
Valganciclovir—Angiopathy—Doxorubicin—prostate cancer	0.000142	0.000175	CcSEcCtD
Valganciclovir—Dizziness—Etoposide—prostate cancer	0.000142	0.000175	CcSEcCtD
Valganciclovir—Muscle spasms—Epirubicin—prostate cancer	0.000142	0.000175	CcSEcCtD
Valganciclovir—Immune system disorder—Doxorubicin—prostate cancer	0.000142	0.000174	CcSEcCtD
Valganciclovir—Gastrointestinal pain—Capecitabine—prostate cancer	0.000141	0.000174	CcSEcCtD
Valganciclovir—Mediastinal disorder—Doxorubicin—prostate cancer	0.000141	0.000174	CcSEcCtD
Valganciclovir—Abdominal pain—Docetaxel—prostate cancer	0.000141	0.000174	CcSEcCtD
Valganciclovir—Body temperature increased—Docetaxel—prostate cancer	0.000141	0.000174	CcSEcCtD
Valganciclovir—Chills—Doxorubicin—prostate cancer	0.000141	0.000173	CcSEcCtD
Valganciclovir—Musculoskeletal discomfort—Prednisone—prostate cancer	0.00014	0.000173	CcSEcCtD
Valganciclovir—Arrhythmia—Doxorubicin—prostate cancer	0.00014	0.000172	CcSEcCtD
Valganciclovir—Insomnia—Prednisone—prostate cancer	0.000139	0.000171	CcSEcCtD
Valganciclovir—Vision blurred—Epirubicin—prostate cancer	0.000139	0.000171	CcSEcCtD
Valganciclovir—Alopecia—Doxorubicin—prostate cancer	0.000139	0.000171	CcSEcCtD
Valganciclovir—Paraesthesia—Prednisone—prostate cancer	0.000138	0.00017	CcSEcCtD
Valganciclovir—Mental disorder—Doxorubicin—prostate cancer	0.000137	0.000169	CcSEcCtD
Valganciclovir—Urticaria—Capecitabine—prostate cancer	0.000137	0.000169	CcSEcCtD
Valganciclovir—Ill-defined disorder—Epirubicin—prostate cancer	0.000137	0.000169	CcSEcCtD
Valganciclovir—Body temperature increased—Capecitabine—prostate cancer	0.000137	0.000168	CcSEcCtD
Valganciclovir—Abdominal pain—Capecitabine—prostate cancer	0.000137	0.000168	CcSEcCtD
Valganciclovir—Vomiting—Etoposide—prostate cancer	0.000137	0.000168	CcSEcCtD
Valganciclovir—Malnutrition—Doxorubicin—prostate cancer	0.000137	0.000168	CcSEcCtD
Valganciclovir—Anaemia—Epirubicin—prostate cancer	0.000136	0.000168	CcSEcCtD
Valganciclovir—Agitation—Epirubicin—prostate cancer	0.000136	0.000167	CcSEcCtD
Valganciclovir—Dyspepsia—Prednisone—prostate cancer	0.000136	0.000167	CcSEcCtD
Valganciclovir—Dermatitis—Etoposide—prostate cancer	0.000135	0.000167	CcSEcCtD
Valganciclovir—Headache—Etoposide—prostate cancer	0.000135	0.000166	CcSEcCtD
Valganciclovir—Flatulence—Doxorubicin—prostate cancer	0.000135	0.000166	CcSEcCtD
Valganciclovir—Tension—Doxorubicin—prostate cancer	0.000134	0.000165	CcSEcCtD
Valganciclovir—Decreased appetite—Prednisone—prostate cancer	0.000134	0.000165	CcSEcCtD
Valganciclovir—Dysgeusia—Doxorubicin—prostate cancer	0.000134	0.000165	CcSEcCtD
Valganciclovir—Malaise—Epirubicin—prostate cancer	0.000133	0.000164	CcSEcCtD
Valganciclovir—Fatigue—Prednisone—prostate cancer	0.000133	0.000163	CcSEcCtD
Valganciclovir—Nervousness—Doxorubicin—prostate cancer	0.000133	0.000163	CcSEcCtD
Valganciclovir—Vertigo—Epirubicin—prostate cancer	0.000133	0.000163	CcSEcCtD
Valganciclovir—Leukopenia—Epirubicin—prostate cancer	0.000132	0.000163	CcSEcCtD
Valganciclovir—Back pain—Doxorubicin—prostate cancer	0.000132	0.000163	CcSEcCtD
Valganciclovir—Constipation—Prednisone—prostate cancer	0.000132	0.000162	CcSEcCtD
Valganciclovir—Hypersensitivity—Docetaxel—prostate cancer	0.000132	0.000162	CcSEcCtD
Valganciclovir—Muscle spasms—Doxorubicin—prostate cancer	0.000131	0.000162	CcSEcCtD
Valganciclovir—Cough—Epirubicin—prostate cancer	0.000129	0.000158	CcSEcCtD
Valganciclovir—Vision blurred—Doxorubicin—prostate cancer	0.000129	0.000158	CcSEcCtD
Valganciclovir—Asthenia—Docetaxel—prostate cancer	0.000128	0.000158	CcSEcCtD
Valganciclovir—Convulsion—Epirubicin—prostate cancer	0.000128	0.000157	CcSEcCtD
Valganciclovir—Nausea—Etoposide—prostate cancer	0.000128	0.000157	CcSEcCtD
Valganciclovir—Hypertension—Epirubicin—prostate cancer	0.000127	0.000157	CcSEcCtD
Valganciclovir—Hypersensitivity—Capecitabine—prostate cancer	0.000127	0.000157	CcSEcCtD
Valganciclovir—Feeling abnormal—Prednisone—prostate cancer	0.000127	0.000156	CcSEcCtD
Valganciclovir—Ill-defined disorder—Doxorubicin—prostate cancer	0.000127	0.000156	CcSEcCtD
Valganciclovir—Pruritus—Docetaxel—prostate cancer	0.000126	0.000155	CcSEcCtD
Valganciclovir—Anaemia—Doxorubicin—prostate cancer	0.000126	0.000155	CcSEcCtD
Valganciclovir—Gastrointestinal pain—Prednisone—prostate cancer	0.000126	0.000155	CcSEcCtD
Valganciclovir—Arthralgia—Epirubicin—prostate cancer	0.000126	0.000155	CcSEcCtD
Valganciclovir—Agitation—Doxorubicin—prostate cancer	0.000125	0.000154	CcSEcCtD
Valganciclovir—Anxiety—Epirubicin—prostate cancer	0.000125	0.000154	CcSEcCtD
Valganciclovir—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	0.000125	0.000154	CcSEcCtD
Valganciclovir—Discomfort—Epirubicin—prostate cancer	0.000124	0.000153	CcSEcCtD
Valganciclovir—Asthenia—Capecitabine—prostate cancer	0.000124	0.000153	CcSEcCtD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—PPARA—prostate cancer	0.000123	0.000689	CbGpPWpGaD
Valganciclovir—Malaise—Doxorubicin—prostate cancer	0.000123	0.000152	CcSEcCtD
Valganciclovir—Dry mouth—Epirubicin—prostate cancer	0.000123	0.000151	CcSEcCtD
Valganciclovir—Vertigo—Doxorubicin—prostate cancer	0.000123	0.000151	CcSEcCtD
Valganciclovir—Urticaria—Prednisone—prostate cancer	0.000122	0.000151	CcSEcCtD
Valganciclovir—Pruritus—Capecitabine—prostate cancer	0.000122	0.000151	CcSEcCtD
Valganciclovir—Leukopenia—Doxorubicin—prostate cancer	0.000122	0.00015	CcSEcCtD
Valganciclovir—Diarrhoea—Docetaxel—prostate cancer	0.000122	0.00015	CcSEcCtD
Valganciclovir—Abdominal pain—Prednisone—prostate cancer	0.000122	0.00015	CcSEcCtD
Valganciclovir—Body temperature increased—Prednisone—prostate cancer	0.000122	0.00015	CcSEcCtD
Valganciclovir—Confusional state—Epirubicin—prostate cancer	0.000121	0.000149	CcSEcCtD
Valganciclovir—Oedema—Epirubicin—prostate cancer	0.00012	0.000148	CcSEcCtD
Valganciclovir—Anaphylactic shock—Epirubicin—prostate cancer	0.00012	0.000148	CcSEcCtD
Valganciclovir—Infection—Epirubicin—prostate cancer	0.00012	0.000147	CcSEcCtD
Valganciclovir—Cough—Doxorubicin—prostate cancer	0.000119	0.000147	CcSEcCtD
Valganciclovir—Convulsion—Doxorubicin—prostate cancer	0.000118	0.000146	CcSEcCtD
Valganciclovir—Diarrhoea—Capecitabine—prostate cancer	0.000118	0.000146	CcSEcCtD
Valganciclovir—Nervous system disorder—Epirubicin—prostate cancer	0.000118	0.000145	CcSEcCtD
Valganciclovir—Dizziness—Docetaxel—prostate cancer	0.000118	0.000145	CcSEcCtD
Valganciclovir—Thrombocytopenia—Epirubicin—prostate cancer	0.000118	0.000145	CcSEcCtD
Valganciclovir—Hypertension—Doxorubicin—prostate cancer	0.000118	0.000145	CcSEcCtD
Valganciclovir—Tachycardia—Epirubicin—prostate cancer	0.000118	0.000145	CcSEcCtD
Valganciclovir—Skin disorder—Epirubicin—prostate cancer	0.000117	0.000144	CcSEcCtD
Valganciclovir—Hyperhidrosis—Epirubicin—prostate cancer	0.000116	0.000143	CcSEcCtD
Valganciclovir—Arthralgia—Doxorubicin—prostate cancer	0.000116	0.000143	CcSEcCtD
Valganciclovir—Anxiety—Doxorubicin—prostate cancer	0.000116	0.000143	CcSEcCtD
Valganciclovir—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	0.000115	0.000142	CcSEcCtD
Valganciclovir—Discomfort—Doxorubicin—prostate cancer	0.000115	0.000141	CcSEcCtD
Valganciclovir—Anorexia—Epirubicin—prostate cancer	0.000115	0.000141	CcSEcCtD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—PPARA—prostate cancer	0.000114	0.000639	CbGpPWpGaD
Valganciclovir—Dizziness—Capecitabine—prostate cancer	0.000114	0.000141	CcSEcCtD
Valganciclovir—Dry mouth—Doxorubicin—prostate cancer	0.000114	0.00014	CcSEcCtD
Valganciclovir—Vomiting—Docetaxel—prostate cancer	0.000113	0.00014	CcSEcCtD
Valganciclovir—Hypersensitivity—Prednisone—prostate cancer	0.000113	0.00014	CcSEcCtD
Valganciclovir—Hypotension—Epirubicin—prostate cancer	0.000113	0.000139	CcSEcCtD
Valganciclovir—Dermatitis—Docetaxel—prostate cancer	0.000112	0.000138	CcSEcCtD
Valganciclovir—Confusional state—Doxorubicin—prostate cancer	0.000112	0.000138	CcSEcCtD
Valganciclovir—Headache—Docetaxel—prostate cancer	0.000112	0.000138	CcSEcCtD
Valganciclovir—Oedema—Doxorubicin—prostate cancer	0.000111	0.000137	CcSEcCtD
Valganciclovir—Anaphylactic shock—Doxorubicin—prostate cancer	0.000111	0.000137	CcSEcCtD
Valganciclovir—Infection—Doxorubicin—prostate cancer	0.000111	0.000136	CcSEcCtD
Valganciclovir—Asthenia—Prednisone—prostate cancer	0.00011	0.000136	CcSEcCtD
Valganciclovir—Vomiting—Capecitabine—prostate cancer	0.00011	0.000135	CcSEcCtD
Valganciclovir—Musculoskeletal discomfort—Epirubicin—prostate cancer	0.00011	0.000135	CcSEcCtD
Valganciclovir—Nervous system disorder—Doxorubicin—prostate cancer	0.000109	0.000135	CcSEcCtD
Valganciclovir—Thrombocytopenia—Doxorubicin—prostate cancer	0.000109	0.000134	CcSEcCtD
Valganciclovir—Pruritus—Prednisone—prostate cancer	0.000109	0.000134	CcSEcCtD
Valganciclovir—Insomnia—Epirubicin—prostate cancer	0.000109	0.000134	CcSEcCtD
Valganciclovir—Dermatitis—Capecitabine—prostate cancer	0.000109	0.000134	CcSEcCtD
Valganciclovir—Tachycardia—Doxorubicin—prostate cancer	0.000109	0.000134	CcSEcCtD
Valganciclovir—Headache—Capecitabine—prostate cancer	0.000108	0.000133	CcSEcCtD
Valganciclovir—Skin disorder—Doxorubicin—prostate cancer	0.000108	0.000133	CcSEcCtD
Valganciclovir—Paraesthesia—Epirubicin—prostate cancer	0.000108	0.000133	CcSEcCtD
Valganciclovir—Hyperhidrosis—Doxorubicin—prostate cancer	0.000108	0.000133	CcSEcCtD
Valganciclovir—Dyspnoea—Epirubicin—prostate cancer	0.000107	0.000132	CcSEcCtD
Valganciclovir—Somnolence—Epirubicin—prostate cancer	0.000107	0.000132	CcSEcCtD
Valganciclovir—Anorexia—Doxorubicin—prostate cancer	0.000106	0.000131	CcSEcCtD
Valganciclovir—Nausea—Docetaxel—prostate cancer	0.000106	0.000131	CcSEcCtD
Valganciclovir—Dyspepsia—Epirubicin—prostate cancer	0.000106	0.00013	CcSEcCtD
Valganciclovir—Diarrhoea—Prednisone—prostate cancer	0.000105	0.00013	CcSEcCtD
Valganciclovir—Decreased appetite—Epirubicin—prostate cancer	0.000105	0.000129	CcSEcCtD
Valganciclovir—Hypotension—Doxorubicin—prostate cancer	0.000104	0.000128	CcSEcCtD
Valganciclovir—Gastrointestinal disorder—Epirubicin—prostate cancer	0.000104	0.000128	CcSEcCtD
Valganciclovir—Fatigue—Epirubicin—prostate cancer	0.000104	0.000128	CcSEcCtD
Valganciclovir—Constipation—Epirubicin—prostate cancer	0.000103	0.000127	CcSEcCtD
Valganciclovir—Pain—Epirubicin—prostate cancer	0.000103	0.000127	CcSEcCtD
Valganciclovir—Nausea—Capecitabine—prostate cancer	0.000103	0.000126	CcSEcCtD
Valganciclovir—Dizziness—Prednisone—prostate cancer	0.000102	0.000125	CcSEcCtD
Valganciclovir—Musculoskeletal discomfort—Doxorubicin—prostate cancer	0.000101	0.000125	CcSEcCtD
Valganciclovir—Insomnia—Doxorubicin—prostate cancer	0.000101	0.000124	CcSEcCtD
Valganciclovir—Paraesthesia—Doxorubicin—prostate cancer	0.0001	0.000123	CcSEcCtD
Valganciclovir—Dyspnoea—Doxorubicin—prostate cancer	9.93e-05	0.000122	CcSEcCtD
Valganciclovir—Feeling abnormal—Epirubicin—prostate cancer	9.92e-05	0.000122	CcSEcCtD
Valganciclovir—Somnolence—Doxorubicin—prostate cancer	9.9e-05	0.000122	CcSEcCtD
Valganciclovir—Gastrointestinal pain—Epirubicin—prostate cancer	9.85e-05	0.000121	CcSEcCtD
Valganciclovir—Dyspepsia—Doxorubicin—prostate cancer	9.81e-05	0.000121	CcSEcCtD
Valganciclovir—Vomiting—Prednisone—prostate cancer	9.79e-05	0.000121	CcSEcCtD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—CREBBP—prostate cancer	9.78e-05	0.000547	CbGpPWpGaD
Valganciclovir—Dermatitis—Prednisone—prostate cancer	9.7e-05	0.000119	CcSEcCtD
Valganciclovir—Decreased appetite—Doxorubicin—prostate cancer	9.68e-05	0.000119	CcSEcCtD
Valganciclovir—Headache—Prednisone—prostate cancer	9.64e-05	0.000119	CcSEcCtD
Valganciclovir—Gastrointestinal disorder—Doxorubicin—prostate cancer	9.62e-05	0.000118	CcSEcCtD
Valganciclovir—Fatigue—Doxorubicin—prostate cancer	9.6e-05	0.000118	CcSEcCtD
Valganciclovir—Urticaria—Epirubicin—prostate cancer	9.57e-05	0.000118	CcSEcCtD
Valganciclovir—Pain—Doxorubicin—prostate cancer	9.53e-05	0.000117	CcSEcCtD
Valganciclovir—Constipation—Doxorubicin—prostate cancer	9.53e-05	0.000117	CcSEcCtD
Valganciclovir—Body temperature increased—Epirubicin—prostate cancer	9.52e-05	0.000117	CcSEcCtD
Valganciclovir—Abdominal pain—Epirubicin—prostate cancer	9.52e-05	0.000117	CcSEcCtD
Valganciclovir—Feeling abnormal—Doxorubicin—prostate cancer	9.18e-05	0.000113	CcSEcCtD
Valganciclovir—Nausea—Prednisone—prostate cancer	9.14e-05	0.000113	CcSEcCtD
Valganciclovir—Gastrointestinal pain—Doxorubicin—prostate cancer	9.11e-05	0.000112	CcSEcCtD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—CREBBP—prostate cancer	9.08e-05	0.000508	CbGpPWpGaD
Valganciclovir—Hypersensitivity—Epirubicin—prostate cancer	8.87e-05	0.000109	CcSEcCtD
Valganciclovir—Urticaria—Doxorubicin—prostate cancer	8.85e-05	0.000109	CcSEcCtD
Valganciclovir—Abdominal pain—Doxorubicin—prostate cancer	8.81e-05	0.000108	CcSEcCtD
Valganciclovir—Body temperature increased—Doxorubicin—prostate cancer	8.81e-05	0.000108	CcSEcCtD
Valganciclovir—Asthenia—Epirubicin—prostate cancer	8.64e-05	0.000106	CcSEcCtD
Valganciclovir—Pruritus—Epirubicin—prostate cancer	8.52e-05	0.000105	CcSEcCtD
Valganciclovir—Diarrhoea—Epirubicin—prostate cancer	8.24e-05	0.000101	CcSEcCtD
Valganciclovir—Hypersensitivity—Doxorubicin—prostate cancer	8.21e-05	0.000101	CcSEcCtD
Valganciclovir—Asthenia—Doxorubicin—prostate cancer	7.99e-05	9.84e-05	CcSEcCtD
Valganciclovir—Dizziness—Epirubicin—prostate cancer	7.96e-05	9.8e-05	CcSEcCtD
Valganciclovir—Pruritus—Doxorubicin—prostate cancer	7.88e-05	9.7e-05	CcSEcCtD
Valganciclovir—Vomiting—Epirubicin—prostate cancer	7.66e-05	9.42e-05	CcSEcCtD
Valganciclovir—Diarrhoea—Doxorubicin—prostate cancer	7.62e-05	9.38e-05	CcSEcCtD
Valganciclovir—Dermatitis—Epirubicin—prostate cancer	7.58e-05	9.34e-05	CcSEcCtD
Valganciclovir—Headache—Epirubicin—prostate cancer	7.54e-05	9.29e-05	CcSEcCtD
Valganciclovir—Dizziness—Doxorubicin—prostate cancer	7.37e-05	9.07e-05	CcSEcCtD
Valganciclovir—Nausea—Epirubicin—prostate cancer	7.15e-05	8.8e-05	CcSEcCtD
Valganciclovir—Vomiting—Doxorubicin—prostate cancer	7.08e-05	8.72e-05	CcSEcCtD
Valganciclovir—Dermatitis—Doxorubicin—prostate cancer	7.02e-05	8.64e-05	CcSEcCtD
Valganciclovir—Headache—Doxorubicin—prostate cancer	6.98e-05	8.59e-05	CcSEcCtD
Valganciclovir—Nausea—Doxorubicin—prostate cancer	6.62e-05	8.15e-05	CcSEcCtD
